ABOUT
Insight - Innovation - Access - Engagement - Partnering
The global partnering and investment summit for global leaders and innovators in CNS neuroscience and psychiatric drug discovery, development, platforms and technologies.
Convened by-invitation, Bio-Neuroscience is a high level, boutique gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups crucial to the discovery, development and market launch of novel therapeutics and breakthrough platforms and technologies.
High level access, serious, sustained engagement, discussion and networking with key stakeholders. Sharing models, lessons learned, solutions, ways forward and best practices. A truly curated and unique summit to facilitate business and accelerate innovation.
ADVISORY BOARD
We are honored by the support of our Advisory Board.
Meet them in person at the summit.
 Stacie WeningerExecutive Director - F-Prime Biomedical Research Initiative |  David ReynoldsVenture Partner - SV Health Investors, CEO - LoQus23 Therapeutics |  Sourav KoleManaging Director - Dolby Family Ventures |  Joachim ScholppGlobal Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim |
|---|---|---|---|
 Kalpana Merchant, PhDChief Scientific Officer - Retromer Therapeutics, Adjunct Professor of Neurology - Northwestern University Feinberg School of Medicine. |  Juan Carlos LopezManaging Director, Research Grants - RTW Charitable Foundation. Formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience |  Mark TreherneCommercial Scientist, Entrepreneur & Investor. Chairperson - Monument Therapeutics, Talisman Therapeutics, Ubiqent, NuVision Biotherapies |  Pieter van BokhovenChief Scientific Officer - Amsterdam Neuroscience IAO - VUMC |
 Andrea Soto Padilla, M.D. PhDBusiness Development - Amsterdam UMC |  Pawel ŚwiebodaFounder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA. |  Hakan GokerManaging Director, Head of Healthcare & Life Sciences - M-Ventures |  Christian J. SuojanenFounder & CEO - Broadreach Global, Member of the Board - European Brain Foundation |
SPEAKERS
Meet the speakers:
 Florian BrandCEO & Co-Founder - atai Life Sciences |  Mary Chamberlain-TharpChief Business Officer – Neumora |  Philip ScheltensHead of the Dementia Fund, Partner - EQT Life Sciences, Professor of Neurology - Amsterdam University Medical Center |  Olga KrylovaDirector Of Business Development & Innovation - Otsuka Pharmaceutical Companies Europe |
|---|---|---|---|
 Christian ThomsenGlobal Head of CNS BD&L - Boehringer Ingelheim |  Raúl Martín-RuizPartner - Ysios Capital |  Claire LeurentManaging Director - Abbvie Ventures |  Cillian KingManaging Director - EQT Life Sciences |
 Jasper BosGeneral Partner - Forbion |  Martien KasPresident - European College of NeuroPsychopharmacology (ECNP), Professor of Behavioral Neuroscience - Groningen Institute for Evolutionary Life Sciences, University of Groningen |  Dee DattaCEO - Switch Therapeutics |  Niels PlathChief Scientific Officer - Muna Therapeutics |
 José Luis LanciegoChair - International Brain Research Organization Pan-European Committee, Head, Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program - CIMA, University of Navarra |  Kees BeenChief Executive Officer - Kynexis Therapeutics, Inc |  Aaron KoenigChief Medical Officer - Delix Therapeutics |  Craig ThompsonChief Executive Officer - Cerevance |
 Maria Luisa PinedaCEO & Co-Founder - Envisagenics |  Jim SullivanCo-Founder & CEO - Vanqua Bio |  Yael WeissCEO - Mahzi Therapeutics |  Frédéric DestrebecqExecutive Director - European Brain Council |
 Terry PirovolakisFounder & CEO - Elpida Therapeutics |  Anela VukojaCOO - Apollo Health Ventures |  Carlos BuesaFounder & Chairman of the Board - Oryzon |  John KasteleinCSO - New Amsterdam Pharma, Operating Partner - Forbion, |
 Anta GkelouPrincipal - Sofinnova Partners (to be confirmed) |  Jason DictenbergCEO – SpliceRNA, Advisory Board Member – Alzheimers Drug Discovery Foundation, New York |  Arno de WildeDirector - EQT Life Sciences |  Rowan GardnerCo-founder and Chief Business & Investment Officer - PrecisionLife |
 Hilgo BruiningProfessor, Neurobiological developmental disorders -Amsterdam UMC. Head - N=You Neurodevelopmental Precision Center |  Delphine CharvinOperating Partner - ARGOBIO Studio |
WHO'S COMING?
Two days of sustained, interactive discussion, networking and partnering with:
Industry Leaders
Senior industry leaders from pharma, large biotech and healthcare companies. Heads of therapeutic area, R&D, clinical development, biological sciences, M&A, scouting, business development & licensing.
Key Opinion Leaders
Key Opinion Leaders from all stakeholder groups crucial to the successful development, approval and market launch of novel CNS neuroscience and psychiatric therapeutics, platforms and technologies.
Founders & CEOs
From startup and growth companies at the cutting edge of the future of CNS neuroscience and psychiatric drug discovery, development, advanced therapies, platforms and technologies.
Government & NGOs
Public agencies, funding bodies, foundations, societies, associations, patient organizations & NGOs in CNS neurosciences and psychiatry.
Investors
In CNS neuroscience and psychiatric drug development, platforms and technologies.
VC and corporate venture, private equity, family offices, angels & HNW.
Leading Advisors
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.
PRESENTING COMPANIES
A curated selection of the best, world-class , innovative CNS neurosciences and psychiatric drug development companies with potential to transform healthcare, patient outcomes or markets. Selection is by excellence and potential, not by price tag.
There is no cost to present beyond the regular startup or private company registration fees.
Presenting Companies Receive:
- A 3 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors and industry: In the plenary session.
- Exclusive post presentation meeting space:
- Meeting Space: You one of five reserved meeting spaces prominently placed next to the main networking area.
- For 30 minutes in the networking break immediately following the presentation session.
- 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience and psychiatric drug development and biopharma.
- Full access to the summit programme.
- Option to add an exclusive company exhibition stand.
SCHEDULE
Day I -
Feb. 14
08:15 - REGISTRATION OPENS, COFFEE & NETWORKING
09:00 - Official Inauguration and Welcome
09:15 - CNS Neurosciences and Psychiatry – Policy to accelerate a new generation of novel therapeutics.
09:45 - From outward symptoms to underlying biology – where the science is going in ND & psychiatry.
10:30 - COFFEE & NETWORKING BREAK
11:15 - Enhancing patient selection and clinical trials design for rational drug development in ND disease.
12:00 - The move to increasing precision medicine approaches in psychiatric drug development.
12:45 - LUNCH & NETWORKING BREAK
13:45 - Investor Session - The early-stage CNS neuroscience investor perspective.
14:30 - COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.
15:15 - COFFEE & NETWORKING BREAK
15:45 - Gene Therapy, RNA and Advanced Therapies in Neurodegenerative Disease.
16:45 - COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.
17:30 - END OF DAY I PROGRAM & NETWORKING RECEPTION
Day II -
Feb. 15
08:15 - REGISTRATION OPENS, COFFEE & NETWORKING
09:00 - Official Inauguration and Welcome
09:15 - Advanced therapeutics in rare neurological diseases; the potential, challenges, and strategies.
10:00 - Growth company panel: Advancing the pipeline and navigating current market conditions.
10:45 - COFFEE & NETWORKING BREAK
11:15 - Industry Panel - Partnering with industry on CNS neuroscience drug development
12:15 - COMPANY PITCH SESSION – 5 Selected startups pitch to an industry & investor panel.
13:00 - LUNCH & NETWORKING BREAK
14:00 - The state of CNS neuroscience drug development, science and investment
14:15 - Biopharma VCs; CNS neuroscience is back
15:00 - Wrap up discussion – Interactive discussion panel between Advisory Board members & participants
15:30 - Bio-Neuroscience Pitch Award – As selected by the investor and industry jury.
15:45 - END OF SUMMIT - NETWORKING
VENUE
Rosarium
Amstelpark 1, Europaboulevard,
1083 HZ Amsterdam, Netherlands
Rosarium Amstelpark is one of the most presitigious meeting venues in Amsterdam, providing exceptional space for for plenary sessions, meetings and networking. With an open lobby area, wine bar, and adjacent Floriade gardens, it is a unique venue for a high level, by invitation summit like Bio-Neuroscience. Easily accessible by car (parking available), train, or boat.
HOTELS
We suggest that participants reserve in one of the many hotels close to the venue, which you can see in Google Maps above. In particular we recommend the following hotels. There is no retained travel agent for hotel reservations, so please disregard any unsolicited messages offering official accommodations or bookings; we recommend you book either directly with the hotels or via your preferred online booking site or travel agent.
CO-ORGANIZED BY
HOST PARTNER
ORGANIZING PARTNER
GOLD SPONSOR
SILVER SPONSOR
PARTNERS & EXHIBITORS
GET IN TOUCH
Reach us here if you like to
-
Nominate a speaker
-
Apply to present your company or technology
-
Enquire about sponsorship & exhibition opportunities
Be the first to know
Subscribe and be among the first to receive all Broadreach Global updates, announcements and invitations.
Please make sure to double check your email address.
A Broadreach Global Initiative
Contact us at:
Follow us
